Brief: Strides Pharma Science Aiming For Net Debt Reduction Of 5 Billion Rupees In Fy25

Strides Pharma Science

22/05/2024 09:47

May 22 (Reuters) - Strides Pharma Science Ltd  SRID.NS :
    * STRIDES PHARMA SCIENCE LTD-  INCREMENTAL GROWTH TO BE
VISIBLE IN
H2FY25 IN US MARKET
    * STRIDES PHARMA SCIENCE - AIMING FOR AN EBITDA OF 9.50
BILLION
RUPEES – 10 BILLION RUPEES FOR FY25
    * STRIDES PHARMA SCIENCE LTD-  AIMING FOR NET DEBT REDUCTION
OF 5
BILLION RUPEES IN FY25
    * STRIDES PHARMA SCIENCE LTD-  CONTINUING CAPEX OF 1,500
MILLION
RUPEES - 2,000 MILLION RUPEES IN FY25
    * STRIDES PHARMA SCIENCE - SEES US BUSINESS REVENUE TO BE IN
RANGE
OF $285- $300 MILLION FOR FY25
    * STRIDES PHARMA SCIENCE LTD-   AIMING FOR REVENUE IN RANGE
OF
$175-190 MILLION FOR ONESOURCE IN FY25
    * STRIDES PHARMA SCIENCE LTD-   AIMING FOR EBITDA IN RANGE
OF
$60-$65 MILLION FOR ONESOURCE IN FY25
    * STRIDES PHARMA SCIENCE - SEES EBITDA MARGIN TO BE IN THE
RANGE
OF 20%- 22% FOR FY25
    * STRIDES PHARMA SCIENCE LTD-   AIM TO ACHIEVE $400 MILLION
IN THE
NEXT 3 YEARS IN US BUSINESS
    *  STRIDES PHARMA SCIENCE - SEES CONTINUING BUSINESS REVENUE
TO
GROW AT 12-15% YOY FOR FY25

Source text for Eikon:  ID: 
Further company coverage:  SRID.NS 

 ((Reuters.Briefs@thomsonreuters.com;))